International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group最新文献

{"title":"Percutaneous microwave ablation of liver tumors: predicted versus actual ablation zones.","authors":"Gonnie C M van Erp, Koen H M Verdonschot, Alexander Broersen, Pim Hendriks, Christiaan G Overduin, Jouke Dijkstra, Mark C Burgmans","doi":"10.1080/02656736.2026.2683504","DOIUrl":"10.1080/02656736.2026.2683504","url":null,"abstract":"<p><strong>Purpose: </strong>To fully exploit the advantages of ablation planning software, discrepancies between predicted and actual ablation zones should be minimized. This study evaluated the volumetric and geometric correspondence between manufacturer-predicted and actual ablation zones following thermal liver ablation.</p><p><strong>Methods: </strong>This multicenter retrospective study included Emprint microwave ablations with intraprocedural needle and post-ablation confirmation CT scans. The needle position was determined on the needle confirmation scan and subsequently registered to the post-ablation contrast-enhanced CT scan. Manufacturer-predicted ablation zones were projected onto segmented actual ablation zones to calculate overlap metrics: Dice similarity coefficient (DSC), average surface distance (ASD), and the under-ablated volume ratio (UAR), defined as the uncovered fraction of the predicted ablation volume. The UAR was correlated with calculated minimal ablation margins (MAM) using Spearman's rank correlation. The Mann-Whitney U test was used to test if metrics differed for patient-specific factors.</p><p><strong>Results: </strong>Forty-seven ablations were analyzed. Median predicted and actual ablation volumes were 23.3 cm³ [IQR: 18.0-27.4] and 19.0 cm³ [13.9-30.1] (<i>p</i> = 0.22), showing moderate correlation (<i>r</i> = 0.57, <i>p</i> < 0.01). Median DSC was 0.72 [0.64-0.79], ASD 3.1 mm [2.5-3.7], and UAR 0.26 [0.18-0.45]. None of these measures differed significantly by cirrhosis, vascular proximity or subcapsular location. UAR showed a moderate negative correlation with the MAM (r = -0.54, <i>p</i> = 0.0018).</p><p><strong>Conclusion: </strong>Emprint-predicted ablation zones show moderate correspondence with actual ablation zones, with no significant association observed for liver cirrhosis, vascular proximity, or subcapsular location. The observed association between UAR and MAM underscores the need to refine prediction models to achieve adequate ablative margins.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2683504"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multilayered skin-fat-muscle phantom embedded with thermocouples for non-ablative RF heating: numerical simulation and experimental validation.","authors":"Yiyou Ma, Nianou Wang, Ke Li, Huan Liang, Jingfeng Bai, Xiang Ji","doi":"10.1080/02656736.2026.2650762","DOIUrl":"10.1080/02656736.2026.2650762","url":null,"abstract":"<p><strong>Background: </strong>Non-ablative radiofrequency (RF) skin rejuvenation relies on controlled volumetric heating of skin and subcutaneous tissues. Clinical validation is costly and ethically constrained, while simulations require experimental validation. Existing single-layer phantoms cannot capture electrothermal heterogeneities across tissue layers.</p><p><strong>Purpose: </strong>To develop a thermocouple-embedded, skin-fat-muscle-mimicking multilayered phantom (MLP) that simulates electrothermal behavior relevant to RF skin rejuvenation and enables depth-resolved temperature measurement for benchtop evaluation and model validation.</p><p><strong>Methods: </strong>A three-layer MLP (skin, fat, and muscle) was fabricated. Electrical conductivity and thermal properties (thermal conductivity, density, specific heat) were measured and compared with literature-reported human tissue ranges. Three thermocouples were embedded at depths of -1, -3, and -4 mm to record transient temperature under multiple RF voltage settings. A 3D coupled electrothermal simulation was built to replicate the experimental setup, and the simulated results were quantitatively compared with the measured results using temperature difference and temperature rise as primary metrics. A single-layer skin phantom (SLSP) was evaluated in parallel for comparison.</p><p><strong>Results: </strong>MLP properties fell within reported ranges. Simulated temperature profiles showed strong agreement with experiments for both SLSP and MLP (most temperature differences <4%, and most deviation of temperature rise <0.5 °C). Compared with SLSP, MLP simulated temperature rise more closely matches layer-dependent temperature evolution across depth.</p><p><strong>Conclusions: </strong>The MLP with embedded thermocouples provides a reproducible platform for depth-resolved temperature characterization of RF-induced heating and for experimental validation of simulations, supporting efficient screening and benchmarking of RF device settings and electrode designs.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2650762"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148364775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram for predicting HIFU efficacy in uterine fibroids: based on oxytocin-induced arterial-phase perfusion delay and ultrasound features.","authors":"Dan-Ling Zhang, Songsong Wu, Guisheng Ding, XinWei Chen, Sheng Chen","doi":"10.1080/02656736.2026.2630909","DOIUrl":"10.1080/02656736.2026.2630909","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to develop and validate a nomogram for predicting high-intensity focused ultrasound (HIFU) ablation efficacy in uterine fibroids, based on the Oxytocin-Induced Arterial-phase Perfusion Delay Time(APDT) on contrast-enhanced ultrasound (CEUS), combined with ultrasound features.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 53 patients (76 fibroids) who underwent oxytocin-assisted HIFU treatment. All patients underwent abdominal ultrasound before HIFU, with APDT on CEUS recorded pre- and post-oxytocin challenge. Predictive factors were identified via univariate and multivariate logistic regression analyses. A clinical efficacy prediction model for HIFU treatment was established using R software and visualized as a nomogram. Its discriminative ability, calibration performance, and clinical utility were evaluated.</p><p><strong>Results: </strong>The final predictive factors included the number of intratumoral attenuation bands, oxytocin-induced APDT, peripheral blood flow grade, and location/type of fibroids. The nomogram's calibration curve demonstrated excellent agreement between observed and predicted values (absolute error = 0.034). The discriminative ability, assessed by the area under the receiver operating characteristic curve (AUC), was 0.884 (95% CI: 0.803-0.965). The model achieved a sensitivity of 92.7% and specificity of 76.2%, indicating strong predictive value for ablation outcomes. Decision curve analysis revealed high clinical utility with a maximum net benefit threshold probability range of 0%-97%.</p><p><strong>Conclusion: </strong>The HIFU ablation efficacy prediction model, integrating oxytocin-induced Arterial-phase Perfusion Delay Time and ultrasound features, demonstrated robust predictive performance and may assist clinicians in selecting suitable candidates for HIFU treatment.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2630909"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incomplete thermal ablation accelerates local and systemic tumor progression in an immunocompetent prostate cancer model.","authors":"Avan Kader, Marie-Luise Helene Hildegard Ranner-Hafferl, Anna-Lena Polz, Michael Mülleder, Vadim Farztdinov, Annika Fendler, Federico Collettini, Timo Alexander Auer","doi":"10.1080/02656736.2026.2636637","DOIUrl":"10.1080/02656736.2026.2636637","url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate the effects of sublethal hyperthermia on tumor growth of residual tumors in an immune-competent mouse model of prostate cancer.</p><p><strong>Materials and methods: </strong>The study progressed through sequential experiments to assess the effects of incomplete thermal ablation, starting with <i>in vitro</i> tests of sublethal heat on Myc-CaP cell growth, followed by <i>in vivo</i> tumor growth studies on FVB mice (<i>n</i> = 84), proteomic analysis of residual tumors, immunohistochemical evaluation of markers of cellular and vascular proliferation as well as immune markers and Western blot analysis of cytokine and growth factor expression over time.</p><p><strong>Results: </strong>During <i>in vitro</i>-testing cells demonstrated a substantial increase in luminescence over time, while the control group remained stable. <i>In vivo</i> iTA led to significantly enhanced tumor growth both at the ablation site and in distant, untreated tumors, with increased cell proliferation, microvascular density, and expression of pro-tumorigenic factors (IL-6, HGF, VEGF). Proteomic analysis revealed that iTA induced strong early responses in wound healing, immune activation, and extracellular matrix remodeling, with systemic effects also seen in contralateral tumors. Immunohistochemistry and Western blot confirmed these findings and showed elevated immune cell infiltration, particularly CD45+ and CD11b + myeloid cells, indicating that iTA triggers a pro-inflammatory and pro-growth tumor microenvironment locally and systemically.</p><p><strong>Conclusion: </strong>iTA can trigger tissue responses that accelerate tumor progression both locally and at distant sites, underscoring the need for careful pretreatment risk assessment (tumor size, achievable margins, proximity to critical structures) and vigilant monitoring of both treated and untreated disease after ablation.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2636637"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical transitions amid rapid expansion: a 16-year retrospective analysis of ultrasound-guided high-intensity Focused ultrasound (USgHIFU) for uterine fibroids and adenomyosis in Korea and the necessity for clinical standardization.","authors":"Jae-Seong Lee, Kye-Hwa Lee","doi":"10.1080/02656736.2026.2700021","DOIUrl":"https://doi.org/10.1080/02656736.2026.2700021","url":null,"abstract":"<p><strong>Background: </strong>Since its introduction in 2010, Ultrasound-guided High-Intensity Focused Ultrasound (USgHIFU) has rapidly expanded in South Korea, despite the absence of widely accepted standardized clinical protocols. This study evaluated the long-term clinical outcomes of USgHIFU and proposed a standardized MRI-integrated treatment framework incorporating MRI-based planning, treatment verification, and structured follow-up.</p><p><strong>Methods: </strong>In this retrospective analysis, we included 2,992 patients (1,620 with uterine fibroids and 1,372 with adenomyosis) treated with USgHIFU between 2010 and 2025. Therapeutic efficacy was assessed using non-perfused volume (NPV) ratio, volume reduction rates (VRR), and reintervention rates. Long-term durability, defined as freedom from reintervention, was evaluated using Kaplan-Meier analysis in 476 patients with follow-up durations of 3-9.7 years.</p><p><strong>Results: </strong>Immediate post-treatment contrast-enhanced MRI demonstrated a mean NPV ratio of 86.5 ± 7.2%, with 94.2% of patients achieving an NPV ratio ≥ 80%. At 12 months, the mean VRRs were 77.4% and 61.4% for fibroids and adenomyosis, respectively. In the long-term follow-up subset (<i>n</i> = 476), volume reduction was maintained and then increased, reaching 78.8% for fibroids and 66.3% for adenomyosis at 3-9.7 years. Freedom from reintervention was 99.1% at 12 months, 98.4% at 3 years, and 97.6% at 9.7 years. No major complications were observed after implementation of the standardized treatment framework.</p><p><strong>Conclusion: </strong>Standardized USgHIFU treatment, achieving an NPV ratio ≥ 80%, is associated with sustained long-term clinical outcomes and a favorable safety profile. These findings support the clinical value of a standardized MRI-integrated treatment framework and may contribute to future clinical standardization of USgHIFU practice.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2700021"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic utility of the platelet-to-thrombin-antithrombin complex ratio in heatstroke: a single-center retrospective analysis.","authors":"Long-Ping He, Shi-Kai Yu, Qing-Wei Lin, Lin-Cui Zhong, Qing-Bo Zeng, Jing-Chun Song","doi":"10.1080/02656736.2026.2668499","DOIUrl":"10.1080/02656736.2026.2668499","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the discriminatory performance of the platelet-to-thrombin-antithrombin complex ratio (PLT/TAT) for differentiating heatstroke from heat exhaustion and to explore its association with 28-day prognosis and disease severity.</p><p><strong>Methods: </strong>This retrospective study analyzed 100 heat illness patients from 2018 to 2025, including 45 with heat exhaustion and 55 with heatstroke. Baseline and admission laboratory data were analyzed using RF, LASSO and SVM-RFE to discern heatstroke risk factors. Diagnostic accuracy of PLT/TAT was evaluated via ROC curve analysis, complemented by Kaplan-Meier and Spearman analyses.</p><p><strong>Results: </strong>LASSO, RF, and SVM-RFE analyses identified PLT/TAT, MYO, GCS, Cr, PLT, TAT, PIC, and Lac as heatstroke predictors. The AUC for PLT/TAT in diagnosing heatstroke was 0.938 (95% CI: 0.893-0.982, <i>p</i> < 0.001). At a threshold value of 30.1, the sensitivity and specificity were 86.7% and 89.1%, respectively. Patients with a PLT/TAT ratio below 30.1 exhibited a 5.826-fold increased risk of mortality compared to those with a PLT/TAT ratio above 30.1. Spearman correlation analysis demonstrated a negative correlation between PLT/TAT and Lac (<i>r</i> = -0.519, <i>p</i> < 0.001) and a positive correlation with the GCS score (<i>r</i> = 0.689, <i>p</i> < 0.001), the PLT/TAT ratio exhibited significant negative correlations with ALT (<i>r</i> = -0.614, <i>p</i> < 0.001), AST (<i>r</i> = -0.713, <i>p</i> < 0.001), Cr (<i>r</i> = -0.499, <i>p</i> < 0.001), CK (<i>r</i> = -0.445, <i>p</i> < 0.001) and DIC score(<i>r</i> = -0.764, <i>p</i> < 0.001). The group with PLT/TAT < 30.1 showed significantly elevated Lac levels and reduced GCS score compared to the group with PLT/TAT > 30.1 (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>The PLT/TAT ratio was associated with heatstroke severity and 28-day survival, making it a promising adjunctive biomarker for diagnosis and risk stratification.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2668499"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148020512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic effect and impact of Cyclin D1 and cyclin-dependent protein kinase 4 expression in patients with vulvar lichen simplex chronicus treated using focused ultrasound.","authors":"Hua-Mei Liu, Fan Zhang, Meng-Yuan Pi, Yu-Mei Lv","doi":"10.1080/02656736.2026.2657474","DOIUrl":"10.1080/02656736.2026.2657474","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the efficacy of focused ultrasound (FU) for vulvar lichen simplex chronicus (VLSC) and its effect on Cyclin D1 and cyclin-dependent kinase 4 (CDK4) expression.</p><p><strong>Methods: </strong>102 skin samples from reproductive-age patients with VLSC were included; all patients received FU treatment and formed the post-treatment group. 50 normal vulvar skin samples served as controls. Clinical efficacy and Vulvar Quality of Life Index (VQLI) were evaluated at 6 months post-treatment. Immunohistochemistry was performed to detect Cyclin D1 and CDK4 expression, quantified by mean optical density (MOD).</p><p><strong>Results: </strong>The total clinical efficacy rate was 95.1%, and post-treatment VQLI scores were significantly decreased. Both the MOD values and prickle to basal layer MOD ratios of Cyclin D1 and CDK4 were significantly higher in the VLSC group than in the control and post-treatment groups, with no significant differences between the control and post-treatment groups.</p><p><strong>Conclusion: </strong>FU effectively alleviates the clinical symptoms of VLSC, an effect associated with the downregulation of abnormally high Cyclin D1 and CDK4 expression and the restoration of their normal distribution pattern in lesional tissues.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2657474"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147725483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, feasibility, and palliative benefit of HIFU combined with PD-1 inhibitors for elderly patients with advanced pancreatic cancer: a real-world retrospective study.","authors":"Guangzhao Li, Baorang Zhu, Ying Liu, Qin Li, Dailian Wang, Jing Li, Wuwei Yang","doi":"10.1080/02656736.2026.2713171","DOIUrl":"https://doi.org/10.1080/02656736.2026.2713171","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer remains largely refractory to immune checkpoint inhibitors. High-intensity focused ultrasound (HIFU) may modulate the immunosuppressive tumor microenvironment via immunogenic cell death, yet clinical evidence on HIFU combined with programmed cell death protein 1 (PD-1) inhibitors in elderly patients is scarce.</p><p><strong>Methods: </strong>This single-center retrospective study enrolled 13 elderly (≥60 years) patients with advanced pancreatic cancer receiving HIFU plus PD-1 inhibitors (January 2017-December 2024). The primary outcome was safety; secondary outcomes included pain relief (numerical rating scale [NRS]; a decrease of ≥2 points considered clinically meaningful), disease control (RECIST 1.1), progression-free survival (PFS), and overall survival (OS). Exploratory analyses comprised a composite risk score (high-sensitivity C-reactive protein, albumin, and CA19-9) and peripheral immune profiling.</p><p><strong>Results: </strong>Median age was 68.0 years; 76.9% had stage IV disease and 61.5% had received ≥2 prior lines of systemic therapy. HIFU-related adverse events occurred in 46.2% (predominantly grade 1-2) and PD-1-related events in 15.4%; no treatment-related deaths occurred. Clinically meaningful pain relief was achieved in 76.9% of patients (10/13; <i>p</i> = 0.0016), with a median NRS reduction of 3.0 points (IQR: 2.0-3.0). Disease control rates were 75.0% (9/12) in the evaluable and 69.2% (9/13) in the intention-to-treat population. Median PFS was 3.2 months (95% CI: 1.9-3.9) and median OS was 3.7 months (95% CI: 2.1-7.2).</p><p><strong>Conclusions: </strong>In this small cohort of elderly, heavily pretreated patients with advanced pancreatic cancer, HIFU combined with PD-1 inhibitors showed a manageable safety profile and notable pain relief. Prospective validation in larger studies is warranted.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2713171"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148674512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noninvasive treatment strategy for abdominal wall desmoid tumors applying high-intensity focused ultrasound.","authors":"Chenlu Hu, Guangrong Ma, Lingying Wang, Luying He, Hong Shen, Xiaoye Hu, Pintong Huang","doi":"10.1080/02656736.2026.2662962","DOIUrl":"https://doi.org/10.1080/02656736.2026.2662962","url":null,"abstract":"<p><strong>Background: </strong>Desmoid tumor (DT) is a rare, locally invasive soft tissue tumor that does not metastasize but has a high recurrence rate after surgery. DTs can be divided into three types: abdominal wall, intra-abdominal and extra-abdominal DTs. The primary treatment options for abdominal wall DT include active surveillance (AS) and surgical resection. However, many patients experience progression during AS, whereas surgical resection carries a high risk of recurrence. Therefore, an effective, noninvasive and safe local treatment method is currently needed in clinical practice.</p><p><strong>Methods: </strong>This study included all patients with abdominal wall DT treated by high-intensity focused ultrasound (HIFU) at the Oncology Department of the Second Affiliated Hospital of Zhejiang University School of Medicine from July 2015 to May 2023. Thermal ablation of the abdominal wall DT was conducted using focused ultrasound beams. Following tumor ablation, treatment outcomes were evaluated for all patients.</p><p><strong>Results: </strong>A total of 55 abdominal wall DT cases underwent HIFU treatment, including 46 and 9 initial and recurrent tumors, respectively. The median follow-up time was 58 months. The median ablation rate for all patients after 1 month of HIFU treatment was 61%. The objective response rate (ORR) and disease control rate (DCR) were 82% (45/55) and 98% (54/55), respectively. Based on disease course, ORRs were 87% and 56% in treatment-naïve patients and re-treated patients, respectively.</p><p><strong>Conclusion: </strong>HIFU demonstrates a high DCR for abdominal wall DT with few side effects, representing an effective treatment, especially for treatment-naïve patients.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2662962"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148687449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging-derived risk score predicts pain recurrence in osteoid osteoma patients undergoing radiofrequency ablation.","authors":"Gesa Helen Pöhler, Pauline Patzelt, Kristian Schneider, Nils Deventer, Michael Hülskamp, Georg Gosheger, Philipp Schindler, Michael Köhler, Michael Raschke, Walter Heindel, Rakan Al-Itaibi, Max Masthoff","doi":"10.1080/02656736.2026.2642925","DOIUrl":"10.1080/02656736.2026.2642925","url":null,"abstract":"<p><strong>Background: </strong>Pain recurrence following regular radiofrequency ablation (RFA) in osteoid osteoma (OO) remains incompletely understood, yet impacts quality of life.</p><p><strong>Purpose: </strong>To detect predictive imaging parameters in OO with symptomatic recurrence.</p><p><strong>Material and methods: </strong>This retrospective, monocentric study included 122 OO patients [median age 19 (16; 27) years, male 78%] January 2010 to May 2024, which underwent T1-weighted dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) (3T) before CT-guided RFA. Pain recurrence was defined as visual analogue scale increase >4/10 occurring >2 weeks post-intervention (22 (18%) patients). Nidus was categorized intra-/extracortical. DCE-MRI relative/maximum (relative) enhancement (M(R)E) (%), time to peak (TTP) (s), wash-in/out rate (s^-1), brevity of enhancement (s) were compared by Wilcoxon rank-sum test. Hazard ratios (HR), multivariate cox proportional hazard regression, receiver operating characteristics and Bayesian were performed.</p><p><strong>Results: </strong>Extracortical nidus occurred more frequently in patients with recurrence (14%) compared to intracortical nidus (5%, <i>p</i> < 0.001). Patients with recurrence had lower MRE [median, 327.2 (IQR, 227.5-393.6)% vs 386.1 (261, 511.6)%; <i>p</i> = 0.038], higher TTP [47.1 (34.5-59.5) vs 32.3 (24.7-46.7); <i>p</i> = 0.002], lower wash-in rate [38.9 (0-107.5) vs. 83.7(30.5-159.7); <i>p</i> = 0.028]. ME [HR 0.2 (95% CI: 0.06, 0.04); <i>p</i> < 0.001], MRE [HR 0.3 (0.1,1); <i>p</i> = 0.042], TTP [HR 6 (1.4, 25.4); <i>p</i> = 0.016], wash-in rate [HR 0.1(0.02, 0.8); <i>p</i> = 0.03] were predictors of recurrence. Extracortical nidus [HR 6.5 (2.1, 19.7); <i>p</i> < 0.001] was predictive. In extracortical nidus-subgroup recurrence probability ≥55% occurred with TTP >40 s, MRE <300%.</p><p><strong>Conclusion: </strong>Imaging-based risk stratification enables personalized treatment approaches for osteoid osteoma patients, who may benefit from alternative ablation protocols such as extended ablation time, higher temperatures.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2642925"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147501614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}